These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38639444)

  • 1. The Treatment of Bruxısm Assocıated With Fluoxetıne Usıng Olanzapine in 10-Year-Old Child: Case Report.
    Adıgüzel Akman Ö
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):440-442. PubMed ID: 38639444
    [No Abstract]   [Full Text] [Related]  

  • 2. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats.
    Xu Y; Lu J; Yao B; Zhang Y; Huang S; Liu J; Zhang Y; Guo Y; Wang X
    Toxicol Appl Pharmacol; 2021 Nov; 431():115735. PubMed ID: 34610281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of a complex patient - intravenous olanzapine use.
    Goh PY; Huang B; Pehlivan N
    Australas Psychiatry; 2018 Dec; 26(6):604-607. PubMed ID: 29745723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.
    Garg S; Gupta D; Rakesh K; Tikka SK
    J Clin Psychopharmacol; 2019; 39(5):523-524. PubMed ID: 31433337
    [No Abstract]   [Full Text] [Related]  

  • 5. Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?
    Jerath AU; Mavrides NA; Coffey BJ
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):241-244. PubMed ID: 30946619
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.
    Detweiler MB; Trinkle DB
    J Clin Psychiatry; 2003 Jul; 64(7):851-2. PubMed ID: 12934994
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?
    Woon LS; Tee CK; Gan LLY; Deang KT; Chan LF
    J Psychiatr Pract; 2018 Mar; 24(2):121-124. PubMed ID: 29509183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
    Shapira NA; Ward HE; Mandoki M; Murphy TK; Yang MC; Blier P; Goodman WK
    Biol Psychiatry; 2004 Mar; 55(5):553-5. PubMed ID: 15023585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine-associated Edema Decreasing Serum Lithium Concentrations: A Case Report.
    Cusimano J; Martin C; VandenBerg A
    J Clin Psychopharmacol; 2020; 40(5):499-500. PubMed ID: 32858619
    [No Abstract]   [Full Text] [Related]  

  • 13. The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.
    Cole JB; Klein LR; Strobel AM; Blanchard SR; Nahum R; Martel ML
    Pediatr Emerg Care; 2020 Feb; 36(2):70-76. PubMed ID: 28697164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.
    Boland X; Chhabra P
    J Psychiatr Pract; 2019 Mar; 25(2):135-138. PubMed ID: 30849062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable olanzapine: post-injection syndrome.
    Prescrire Int; 2017 Feb; 26(179):46. PubMed ID: 30726633
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefit of extending the dosing interval of olanzapine on schizophrenics during maintenance treatment.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Dec; 30():100-101. PubMed ID: 28858761
    [No Abstract]   [Full Text] [Related]  

  • 17. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
    Zanarini MC; Frankenburg FR; Parachini EA
    J Clin Psychiatry; 2004 Jul; 65(7):903-7. PubMed ID: 15291677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Blunted Orally Disintegrating Olanzapine Effect Due to Coadministered Psyllium.
    Merrick C; Madden CA; Capurso NA
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988934
    [No Abstract]   [Full Text] [Related]  

  • 19. Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine.
    Mustafa FA; Nayar A
    Psychopharmacol Bull; 2019 Jun; 49(2):63-64. PubMed ID: 31308585
    [No Abstract]   [Full Text] [Related]  

  • 20. Call for "High-Dose" Olanzapine Research in Treatment-Resistant Psychosis.
    Westermeyer J
    J Nerv Ment Dis; 2019 Jan; 207(1):45-47. PubMed ID: 30575709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.